Yasjudan Rastrama Putra

Yasjudan Rastrama Putra

Auto-generated profile, based on publicly available information

Yasjudan Rastrama Putra

Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr Sardjito General Hospital Yogyakarta, Yogyakarta, Indonesia

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Journal of Breast Cancer
Verified
Journal Article
Open access
PDF file
KTKartika Widayati Taroeno-Hariadi
Kartika Widayati Taroeno-Hariadi
YPYasjudan Rastrama Putra
Yasjudan Rastrama Putra
LCLina Choridah
Lina Choridah
IWIrianiwati Widodo
Irianiwati Widodo
MHmardiah suci hardianti
mardiah suci hardianti
TATeguh Aryandono
Teguh Aryandono
Taroeno-Hariadi KW, et al. J Breast Cancer. 2021 Sep;24:e41. https://doi.org/10.4048/jbc.2021.24.e41

28 November 2022 in Journal of Blood Medicine
Verified
Journal Article
Open access
PDF file
PRPradana Zaky Romadhon
Pradana Zaky Romadhon
AAAmi Ashariati
Ami Ashariati
SBSipirianus Ugroseno Yudho Bintoro
Sipirianus Ugroseno Yudho Bintoro
MTMochammad Thaha
Mochammad Thaha
SSsatriyo dwi suryantoro
satriyo dwi suryantoro
NYNarazah Mohd Yusoff
Narazah Mohd Yusoff
Objective: The emerging renal complications in beta-thalassemia patients have raised the global exchange of views. Despite better survival due to blood transfusion and iron chelation therapy, the previously unrecognized renal complication remain a burden of disease affecting this population —the primary concern on how iron overload and chelation therapy correlated with renal impairment is still controversial. Early detection and diagnosis is crucial in preventing further kidney damage. Therefore, a systematic review was performed to identify markers of kidney complications in beta thalassemia patients with iron overload receiving chelation therapy. Methods: Searches of PubMed, Scopus, Science Direct, and Web of Science were conducted according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) to identify studies of literature reporting renal outcome in β-TM patients with iron overload and receiving chelation therapy. The eligible 17 studies were obtained. Results: uNGAL/NGAL, uNAG/NAG, uKIM-1 are markers that can be used as predictor of renal tubular damage in early renal complications, while Cystatin C and uβ 2MG showed further damage at the glomerular level. Discussion and Conclusion: The renal complication in beta-thalassemia patients with iron overload receiving chelating agent therapy may progress to kidney disease. Early detection using accurate biological markers is a substantial issue that deserves further evaluation to determine prevention and management.

1 September 2022 in Asian Pacific Journal of Cancer Prevention
Verified
Journal Article
Open access
PDF file
KTKartika Widayati Taroeno-Hariadi
Kartika Widayati Taroeno-Hariadi
YPYasjudan R Putra
Yasjudan R Putra
NANina F Ariesta
Nina F Ariesta
HSHemi Sinorita
Hemi Sinorita
MHmardiah suci hardianti
mardiah suci hardianti
TATeguh Aryandono
Teguh Aryandono
Background: Obesity and metabolic syndrome (MetS) have been linked to the risk of developing certain cancers. This study aimed to analyze the association between obesity markers, MetS and survival outcomes of patients with breast cancer. Methods: This study retrospectively investigated patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-), nonmetastatic breast cancer diagnosed between January 2010 and December 2019. Data on clinical conditions, body mass index (BMI), waist-to-hip ratio (WHR), MetS, time of metastasis and death were collected. Results: A total of 223 breast cancer patient records were eligible for analysis. Obesity (BMI ≥ 25) was found in 38.1% of cases. Abdominal obesity measured as WHR ≥ 0.85 was found in 48.9%. Metabolic syndrome was detected in 56.1% of patients and was associated with older age (OR = 2.196, p = 0.005), postmenopausal status (OR = 2.585, p = 0.001), obesity (OR = 5.684, p = 0.001) and abdominal obesity (OR = 2.612, p = 0.001). Obesity was not associated with poor disease-free survival (DFS) or overall survival (OS), while abdominal obesity was modestly associated with poor DFS (HR = 1.539, p = 0.083) and OS (HR = 3.117; p = 0.019). Multivariate analysis revealed that WHR ≥ 0.85 was independently associated with unfavorable DFS (HR = 1.907, p = 0.027). Patients with MetS had a similar survival rate to those with normal metabolism. Conclusion: In Indonesian women with HR+/HER2- breast cancers, obesity and MetS were not associated with poor survival outcomes. The abdominal obesity marker (WHR) was more accurate in predicting unfavorable DFS.

1 September 2024 in JCO Global Oncology
Verified
Journal Article
Closed access
SHSusanna Hilda Hutajulu
Susanna Hilda Hutajulu
DHDaniel Howdon
Daniel Howdon
YPYasjudan Rastrama Putra
Yasjudan Rastrama Putra
SSSusanti Susanti
Susanti Susanti
DHDidik Setyo Heriyanto
Didik Setyo Heriyanto
MAMatthew Allsop
Matthew Allsop
PURPOSE: There has been a global increase in early-onset colorectal cancer (EOCRC), yet there has been very limited exploration of its impact in Indonesia. This study aimed to determine the clinicopathologic characteristics and the overall survival (OS) of EOCRC compared with those of average-onset colorectal cancer (AOCRC). METHODS: Medical records were retrospectively reviewed from all patients presenting with colorectal cancer (CRC) at Dr Sardjito General Hospital (Yogyakarta, Indonesia) between 2016 and 2019. Sociodemographic, clinicopathologic, and treatment variables were extracted. t Tests were used to compare characteristics of EOCRC and AOCRC patient groups. The Cox proportional hazards regression model was used to analyze age and other potential prognostic factors. RESULTS: The total population (N = 1,276) comprised EOCRC (n = 149; 11.7%) and AOCRC (n = 1,127; 88.3%) patients. EOCRC patients were more likely to have a higher education level, be single, have out-of-pocket insurance, be underweight, and have signet ring histology (all P values <.05), compared with AOCRC patients. EOCRC and AOCRC groups had a comparable estimated 5-year OS of 34.2% and 36.9%, respectively. In multivariable analyses, performance status (Eastern Cooperative Oncology Group), hemoglobin level, cancer stage, and treatment intention were independent prognostic factors for OS (all P values <.05). CONCLUSION: To our knowledge, this first major study of EOCRC in Indonesia highlights its role in the overall burden of CRC and its connection with social determinants of health. Patients with EOCRC are more commonly underweight and generally have a higher proportion of signet ring histology than AOCRC, yet OS in both groups is similar. Future research is required to identify risk factors to inform the content and focus of public health education activities, alongside delineating the biology and causes of early and average onset of the disease.